Euroapi (XPAR:EAPI) Current Accrued Expense: €0.0 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:EAPI Euroapi SA XPAR:EAPI
54 GF Score
Price €1.28
GF Value €2.88
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Euroapi Current Accrued Expense?

Euroapi XPAR:EAPI -0.16% 54 Current Accrued Expense is €0.0 Mil as of Dec. 2025. GuruFocus rates XPAR:EAPI with a GF Score™ of 54/100 and a GF Value™ of €2.88 (Possible Value Trap). The stock has 6 warning signs investors should review.

Euroapi's Current Accrued Expense for the quarter that ended in Dec. 2025 was €0.0 Mil.

Euroapi Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Euroapi's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Euroapi Current Accrued Expense Chart

Euroapi Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Euroapi Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XPAR:EAPI
54GF Score
Euroapi SA XPAR:EAPI
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Euroapi Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of €0.0 Mil mean?
Euroapi (XPAR:EAPI) has a Current Accrued Expense of €0.0 Mil as of Dec. 2025. Current Accrued Expense records the total amount of accrued expenses. View historical data on Euroapi and its competitors.
Is Euroapi's Current Accrued Expense too high?
Euroapi's current Current Accrued Expense is €0.0 Mil. Overall, Euroapi has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Euroapi's Current Accrued Expense compare to ZTS and UTHR?
Euroapi's Current Accrued Expense of €0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Drug Manufacturers company?
A good Current Accrued Expense depends on the Drug Manufacturers industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Euroapi and its competitors. Euroapi's current Current Accrued Expense is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Euroapi stock overvalued right now?
Based on GuruFocus' analysis, Euroapi (XPAR:EAPI) is currently considered Possible Value Trap. The stock's GF Value™ is €2.88, compared to a current price of €1.28 — trading 55.7% below its estimated fair value. The current Current Accrued Expense is €0.0 Mil. Euroapi's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Euroapi (XPAR:EAPI), the current Current Accrued Expense is €0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Euroapi (XPAR:EAPI) Overvalued in 2026?

Based on GuruFocus' analysis, Euroapi stock appears to be undervalued. The current stock price of €1.28 is trading 55.7% below its estimated GF Value™ of €2.88. GuruFocus considers Euroapi to be Possible Value Trap.

Key valuation signals for XPAR:EAPI:

  • Current Accrued Expense: €0.0 Mil
  • GF Value™: €2.88 vs. price of €1.28 (55.7% below fair value)
  • GF Score™: 54/100 with 6 warning signs

No single metric tells the full story. See the XPAR:EAPI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Euroapi Business Description

Other Exchanges EAPIF:USA0EAP:UK940:Germany
Address 32 rue Alexandre Duma, Paris, FRA, 75011
Euroapi SA develops, manufactures, markets, and distributes Active Pharmaceutical Ingredients (APIs) and Intermediates used in the formulation of medicines for human and veterinary use, both from originators, generics, and cosmetics. The company offers vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids and hormones, anti-infectives, opiates, analgesics, and others. It also offers Contract Development Manufacturing Organization (CDMO) services to its customers.
54GF Score

Get the complete analysis for XPAR:EAPI

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.28
Price
€2.88
GF Value